Literature DB >> 16931906

A non-invasive method for detection of intestinal mucositis induced by different classes of chemotherapy drugs in the rat.

Gordon S Howarth1, Katie L Tooley, Geoffrey P Davidson, Ross N Butler.   

Abstract

BACKGROUND: The Sucrose Breath Test (SBT) is a simple noninvasive technique for the detection of small intestinal mucositis. AIM: We utilised rat models of intestinal mucositis induced by different classes of chemotherapeutic agents to broaden application of the SBT.
METHODS: Mucositis was induced in rats by injection of Doxorubicin (Dox), Etoposide (Etop), Irinotecan (Irin), or Cyclophosphamide (Cy) and Etop in combination (Cy+Etop). The SBT was carried out following sucrose gavage, 72 h after chemotherapy. At kill, intestinal tissues were collected for mucositis assessments.
RESULTS: SBT for controls was 16.0 +/- 0.6% (mean +/- SEM) cumulative dose at 90 min. Irin, Doxo, Etop, and Cy+Etop significantly decreased the SBT to 53%, 43%, 32% and 30% of saline control values, respectively (p < 0.01) whilst sucrase activity was correspondingly decreased to 60%, 36%, 14% and 2%. There was good concordance with histological mucositis severity in the jejunum, with median scores of 11, 19, 28 and 27. Correlations between SBT, sucrase activity, and histological severity score yielded r(2) values of 0.82.
CONCLUSIONS: The SBT detected mucositis induced by the alkylating agent, anthracycline and DNA-topoisomerase inhibitor classes, facilitating the detection of small intestinal dysfunction, providing a further means to screen newly-developed drugs for intestinal side-effects.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16931906     DOI: 10.4161/cbt.5.9.3117

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  8 in total

1.  The weaned pig as a model for Doxorubicin-induced mucositis.

Authors:  Jamee Martin; Scott C Howard; Asha Pillai; Peter Vogel; Anjaparavanda P Naren; Steven Davis; Karen Ringwald-Smith; Karyl Buddington; Randal K Buddington
Journal:  Chemotherapy       Date:  2014-10-21       Impact factor: 2.544

2.  Chemotherapy-induced bowel obstruction in small cell lung cancer: a case report.

Authors:  Jermaine I G Coward; Nicola-Louise Ding; Roger Feakins; Hermant Kocher; Sanjay Popat; Piotr W Szlosarek
Journal:  Med Oncol       Date:  2011-12-28       Impact factor: 3.064

3.  Substantial decreases in the number and diversity of microbiota during chemotherapy-induced gastrointestinal mucositis in a rat model.

Authors:  Margot Fijlstra; Mithila Ferdous; Anne M Koning; Edmond H H M Rings; Hermie J M Harmsen; Wim J E Tissing
Journal:  Support Care Cancer       Date:  2014-11-08       Impact factor: 3.603

4.  Using the noninvasive (13)C-sucrose breath test to measure intestinal sucrase activity in swine.

Authors:  Robyn Terry; William H E J van Wettere; Alexandra L Whittaker; Paul J Herde; Gordon S Howarth
Journal:  Comp Med       Date:  2012-12       Impact factor: 0.982

5.  Small-intestinal manifestations of dextran sulfate sodium consumption in rats and assessment of the effects of Lactobacillus fermentum BR11.

Authors:  Mark S Geier; Cassie L Smith; Ross N Butler; Gordon S Howarth
Journal:  Dig Dis Sci       Date:  2008-11-13       Impact factor: 3.199

6.  Combined Effects of Muricid Extract and 5-Fluorouracil on Intestinal Toxicity in Rats.

Authors:  Roger Yazbeck; Ruth Lindsay; Catherine A Abbott; Kirsten Benkendorff; Gordon S Howarth
Journal:  Evid Based Complement Alternat Med       Date:  2015-05-13       Impact factor: 2.629

Review 7.  Biomarkers and non-invasive tests for gastrointestinal mucositis.

Authors:  N S S Kuiken; E H H M Rings; N M A Blijlevens; Wim J E Tissing
Journal:  Support Care Cancer       Date:  2017-05-24       Impact factor: 3.603

8.  Intestinal atresia following chemotherapy, presenting as superior mesenteric artery syndrome: A case report.

Authors:  Xing Wang; Jian-Zhong Li; Ying-Hui Yang; Xiao-Li Huang; Yu Wang; Bin Wu
Journal:  Mol Clin Oncol       Date:  2017-07-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.